• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Intravenous thrombolysis for acute ischemic stroke during two COVID-19 outbreaks in China: Wuhan pandemic and Beijing pandemic
The COVID-19 pandemic has had an impact on the emergency department (ED). Door-to-needle time (DNT) could be prolonged for intravenous thrombolysis (IVT) treatment. We aimed to investigate the impact of two CO...
Source: BMC Neurology - May 25, 2023 Category: Neurology Authors: Guangshuo Li, Shang Wang, Chuanying Wang, Yahui Hao, Yunyun Xiong, Zeyu Ding and Xingquan Zhao Tags: Research Source Type: research

Best Practice Recommendations for Stroke Vascular Imaging During Iodinated Contrast Shortage
GE Healthcare© announced on April 19, 2022, that their main factory and distributor of iodinated contrast had experienced a temporary shutdown because of COVID-19 outbreak in Shanghai, China. This, along with other supply chain issues, led to a worldwide shortage of iodinated contrast agents, Omnipaque and Visipaque. Our Comprehensive Stroke Center was confronted with the cascading effect of this iodinated contrast material shortage. We took immediate steps to revise our protocols and processes to continue to provide high-quality care to our stroke patients. A multidisciplinary working group comprised of representativ...
Source: Neurology Clinical Practice - March 3, 2023 Category: Neurology Authors: Bhole, R., Solenski, N. J., Donahue, J. H., Kellogg, R. T., Roach, N. N., Chapman, S. N., Worrall, B. B., Evans, A. J., Patel, S. H., Mukherjee, S., Park, M. S., Southerland, A. M. Tags: Decision analysis, Medical care, All Cerebrovascular disease/Stroke, All Practice Management Commentary Source Type: research

Impact of improved stroke green channel process on the delay of intravenous thrombolysis in patients with acute cerebral infarction during the COVID-19 pandemic: An observational study
ConclusionDuring the two periods of the COVID-19 outbreak (SARS-CoV-2 and Omicron), after the improvement of the green channel for intravenous thrombolysis, there might be some delay in in-hospital DIT during the SARS-CoV-2 outbreak, however, the in-hospital delay indicator DNT for intravenous thrombolysis were not affected.
Source: Frontiers in Neurology - September 26, 2022 Category: Neurology Source Type: research

Telestroke for the Treatment of Ischemic Stroke in Western China During the COVID-19 Pandemic: A Multicenter Observational Study
ConclusionsTelemedicine is effective in improving the thrombolysis administration among patients with IS in Western China. Implementation of the telestroke network should be promoted, especially when access to care is affected by public health emergencies, such as the COVID-19 pandemic.
Source: Frontiers in Neurology - January 31, 2022 Category: Neurology Source Type: research

Delayed Stroke Treatment during COVID-19 Pandemic in China
Conclusions: COVID-19 pandemic has remarkable impacts on the management of AIS. Both pre- and posthospital delays were prolonged significantly, and proportion of patients arrived within the 4.5-h time window for intravenous thrombolysis treatment was decreased. Given that anti-COVID-19 measures are becoming medical routines, efforts are warranted to shorten the delay so that the outcomes of stroke could be improved.Cerebrovasc Dis
Source: Cerebrovascular Diseases - July 9, 2021 Category: Neurology Source Type: research

Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19)
AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, is responsible for the outbreak of coronavirus disease 19 (COVID-19) and was first identified in Wuhan, China in December 2019. It is evident that the COVID-19 pandemic has become a challenging world issue. Although most COVID-19 patients primarily develop respiratory symptoms, an increasing number of neurological symptoms and manifestations associated with COVID-19 have been observed. In this narrative review, we elaborate on proposed neurotropic mechanisms and various neurological symptoms, manifestations, and complications of COVI...
Source: Journal of Neurology - January 23, 2021 Category: Neurology Source Type: research

Stroke epidemiology and COVID-19 pandemic
Purpose of review The aim of this study was to describe the impact of the COVID-19 outbreak on the epidemiology, cause and clinical characteristics of incident stroke in different settings and populations. Recent findings Several studies have shown that there are three main themes in the epidemiology of stroke during the COVID-19 pandemic: COVID-19 seems to be associated with stroke in a significant number of patients. This association has been reported in several clinical series, mainly from China. There is a consistent trend towards a decreased number of hospital admissions of stroke patients during the pandem...
Source: Current Opinion in Neurology - January 21, 2021 Category: Neurology Tags: CEREBROVASCULAR DISEASE: Edited by Valeria Caso Source Type: research

Neurological involvement of coronavirus disease 2019: a systematic review
ConclusionsNeurological manifestations of COVID-19 are not rare, especially large vessel stroke, Guillain –Barre syndrome, and meningoencephalitis. Moving forward, further studies are needed to clarify the prevalence of the neurological complications of SARS-CoV-2 infection, investigate their biological backgrounds, and test treatment options. Physicians should be cautious not to overlook other neurol ogical diagnoses that can mimic COVID-19 during the pandemic.
Source: Journal of Neurology - June 18, 2020 Category: Neurology Source Type: research

Severe acute respiratory syndrome coronavirus 2 is penetrating to dementia research.
Abstract 1. Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus infectious disease 2019 (COVID-19), which was first reported in Wuhan, China, in late December, 2019. Despite the tremendous efforts to control the disease, SARS-CoV-2 has infected 1,5 million people and caused the death of more than a hundred thousand people across the globe as of writing. Recently, Mao et al. [1] investigated the penetration potential of SARS-CoV-2 into the central nervous system in 214 patients. They reported that 36.4% of the patients had some neurologic findings which are ranged from nonsp...
Source: Current Neurovascular Research - May 21, 2020 Category: Neurology Authors: Bostanciklioglu M, Temiz E Tags: Curr Neurovasc Res Source Type: research

Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights
An outbreak of an acute respiratory illness of unknown cause started in Wuhan, Hubei province, China on December 12, 2019.1,2 A new strain of coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in these patients. Subsequently, the identified acute respiratory illness was named coronavirus disease 2019 (COVID-19). Soon thereafter, the COVID-19 epidemic in China became a pandemic with a significant burden on healthcare and the world-wide economy. SARS-CoV-2 has been shown to be a distinct class of the beta coronaviruses (Beta-CoVs) with a 79.5% gene sequence homology to the severe ...
Source: Journal of Stroke and Cerebrovascular Diseases - May 10, 2020 Category: Neurology Authors: Afshin A. Divani, Sasan Andalib, Mario Di Napoli, Simona Lattanzi, M. Shazam Hussain, Jos é Biller, Louise D. McCullough, M. Reza Azarpazhooh, Alina Seletska, Stephan A. Mayer, Michel Torbey Tags: Review Article Source Type: research

Covert COVID-19 complications: Continuing the use of evidence-based drugs to minimize potentially lethal indirect effects of the pandemic in stroke patients
Stroke and cardiovascular diseases are the world's biggest killers, globally accounting for over 15 million deaths each year (https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death). Since the Coronavirus Disease 2019 (COVID-19) outbreak in Wuhan, China and its rapid spread to other countries, as of April 272,020, there were about 3 million cases with over 190,000 deaths worldwide. However, actual situation might be even more dire, since such statistics likely do not fully display the entire impact of COVID-19, especially with regard to its influence on patients with a history of stroke who need to tak...
Source: Journal of the Neurological Sciences - May 5, 2020 Category: Neurology Authors: Meng Lee, Chi-Hsin Sally Chen, Bruce Ovbiagele Tags: Letter to the Editor Source Type: research